Triple antithrombotic therapy and dual therapy - What is the evidence base?

Br J Clin Pharmacol. 2022 Jul;88(7):3009-3012. doi: 10.1111/bcp.15257. Epub 2022 Feb 16.

Authors

Hani Essa^{1

2}, Rajiv Sankaranarayanan^{1

2}, Lauren Walker³

Affiliations

¹ Department of Cardiology, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Longmoor lane, Liverpool, L9 7AL, United Kingdom.
² Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital, Liverpool, UK.
³ Clinical Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.

PMID: 35172379
DOI: 10.1111/bcp.15257

No abstract available

Keywords: acute coronary syndrome; atrial fibrillation; triple antithrombotic therapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Acute Coronary Syndrome* / drug therapy
Anticoagulants / adverse effects
Atrial Fibrillation* / drug therapy
Drug Therapy, Combination
Fibrinolytic Agents / adverse effects
Humans
Platelet Aggregation Inhibitors / adverse effects

Substances

Anticoagulants
Fibrinolytic Agents
Platelet Aggregation Inhibitors